Drugs / ScPvs25
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00295581 | Mar 2005 → Jun 2008 | Plasmodium falciparum malaria, Plasmodium vivax malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ScPvs25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00295581 ↗ |
| Modality | Protein / enzyme biologic | “recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51” PMID 18612426 ↗ Jul 2008 |
| Route | Intramuscular | “The vaccine is injected into the muscle of the upper arm.” NCT00295581 ↗ |